Annexon, Inc. (ANNX) - Forward P/S Multiple
Anticipation of the Phase 3 clinical trial results is driving volatility, where the current value of reflects market optimism for Annexon, Inc. (ANNX). The forward revenue multiple illustrates the demand for the unique blocking of the C1q protein to combat tissue degeneration. An innovative complement therapy platform provides the foundation for growth, establishing new treatment standards for Alzheimer's disease and rare autoimmune pathologies.
Analytical breakdowns for Annexon, Inc.
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Annexon, Inc.|ANNX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Annexon, Inc.|ANNX - Company Aggregate Debts|Debt to Book Capitalization Ratio Annexon Biosciences Inc.|ANNX - Company Long-Term Indebtedness|Company Short-Term Debt Annexon|Quick Liquidity Indicator annexonbio.com
- business earnings and investment ratios data:
ANNX - Company Profit|Expected Profit Annexon, Inc.|ANNX - Price to Earnings Multiple|Forward P/E Multiple Annexon Inc.|ANNX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Annexon Biosciences Inc.|ANNX - Operating profit EBITDA|Earnings per share for the last twelve months Annexon|ANNX - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months annexonbio.com|ANNX - Earnings per share growth rate in current year|Earnings growth forecast for next year Annexon, Inc.
- sales and revenue indicators:
Fundamental company analysis:ANNX (Annexon)
Fundamental asset selection requires analyzing leading indicators to assess business value relative to future cash flows. This metric compares the market capitalization of Annexon, Inc. (ANNX) with expected sales volumes, which, given the high demand for complement inhibitors, allows for an assessment of capitalization potential via the company's modeled P/S ratio as drugs enter the market following regulatory approval.
Competitor analysis for Annexon, Inc.
Biogen - Forward Price-to-Revenue Multiple|Forward Price to Sales NBIX|Regencell - Forward P/S Multiple|Market Cap to Expected Sales Ratio Axsome Corp AXSM|ACADIA Pharmaceuticals (ACAD) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue XENE|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Supernus Pharmaceuticals, Inc. (SUPN)|Forward Price-to-Revenue Multiple CPRX (Catalyst Pharmaceuticals Inc)|Market Cap to Expected Sales Ratio Denali Corp|Forward P/S Multiple HRMY (Harmony Biosciences)|Forward P/S Multiple biohavenpharma.com BHVN|AMLX - Price-to-Projected Revenue Ratio|TRVI (Trevi Therapeutics Inc) - Market Cap to Projected Revenue|Praxis Medicines (PRAX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue AVXL|Forward Price-to-Revenue Multiple CBLL|Market Cap to Projected Revenue PRTA (Prothena Corporation)|Price-to-Projected Revenue Ratio Alector, Inc. (ALEC)|omeros.com - Market Cap to Projected Revenue|Forward P/S Multiple NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Market Cap to Future Revenue Ratio|VYGR: Forward Price-to-Revenue Multiple|NMRA - Forward P/S Multiple|Scilex (SCLX) - Price-to-Projected Revenue Ratio|Tevogen Bio Holdings Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Alpha Cognition Inc|Market Cap to Future Revenue Ratio Cognition Therapeutics Inc. CGTX|Forward P/S Multiple IKT|Forward P/S Multiple cassavasciences.com (SAVA)|Price-to-Projected Revenue Ratio Assertio ASRT|COYA: Market Cap to Projected Revenue|VTGN - Price-to-Projected Revenue Ratio|OVID (Ovid Therapeutics Inc.) - Market Cap to Projected Revenue|ABOS: Forward P/S Multiple|Market Cap to Future Revenue Ratio cervomed.com (CRVO)|Forward Price-to-Revenue Multiple ATHE|Market Cap to Projected Revenue CLNN (Clene Nanomedicine)|Price-to-Projected Revenue Ratio PepGen Inc. (PEPG)|JUNS - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Relmada Therapeutics RLMD|ANVS: Market Cap to Projected Revenue|GRCE: Forward Price-to-Revenue Multiple|Forward Price to Sales AIFF (Firefly Neuroscience, Inc.)|KLTO: Forward P/S Multiple|NRSN - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals|Market Cap to Projected Revenue MTVA (MetaVia, Inc.)|Forward P/S Multiple NRXS|Forward Price-to-Revenue Multiple heliusmedical.com HSDT|Passage Bio - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Neuphoria Therapeutics, Inc. (NEUP)|Minerva Neurosciences - Forward P/S Multiple|ATHA - Forward P/S Multiple|Addex Therapeutics Ltd (ADXN) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ALZN|Price-to-Projected Revenue Ratio Cyclerion Therapeutics Inc.|Market Cap to Projected Revenue PTIX (Protagenic)|Forward Price-to-Revenue Multiple KTTA (Pasithea Therapeutics)|cortigent.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Avenue Therapeutics, Inc. ATXI|BCLI: Market Cap to Projected Revenue|Cara Therapeutics, Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio Chromocell|ELYM (eliemtx.com) - Forward Price-to-Revenue Multiple|Intra-Cellular Therapies, Inc. (ITCI) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Longboard Pharmaceuticals, Inc.|MRNS: Forward Price to Sales|Price-to-Projected Revenue Ratio NKGen (NKGN)|NRBO - Market Cap to Future Revenue Ratio|Forward P/S Multiple SAGE (Sage Therapeutics, Inc.)|Forward P/S Multiple synaptogen.com SNPX|TRVN - Price-to-Projected Revenue Ratio|VIGL (Vigil Neuroscience) - Market Cap to Projected Revenue|Anew Medical (WENA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue CERE
